Retatrutide
Advanced metabolic regulation, from the inside out.
Vial content — available presentations, not a dose.
Retatrutide is a synthetic peptide designed as a single molecule that engages three metabolic receptors at once — GLP-1, GIP, and glucagon. Most metabolic peptides address one receptor, or two; this one was built to speak to all three from the same structure. It is studied for its role in appetite regulation, glucose metabolism, body weight, and energy expenditure, and has been examined in contexts reaching beyond weight alone — metabolic liver disease, obstructive sleep apnea, knee osteoarthritis, and cardiovascular and renal outcomes.
Appetite, blood sugar, and energy expenditure were never separate systems — the body coordinates them through receptors it already carries and hormones it already makes. Retatrutide does not introduce a new instruction into that network. It engages three receptors that are already there, already listening, and is studied for what happens when all three are addressed together rather than one at a time.
How the signal travels.
Retatrutide is a triple agonist: one peptide, three receptor targets. Each belongs to a signaling route the body already uses to read fuel intake and decide what to do with it.
The GLP-1 receptor is one of the two incretin targets in the design. It is engaged here as part of a three-receptor molecule rather than in isolation, which is the premise the research set out to test.
The GIP receptor is the second incretin target. What is under study is not this receptor on its own but what happens when it is engaged by the same molecule as GLP-1.
The glucagon receptor is the third and least familiar arm, and the one that distinguishes this molecule from dual incretin agonists. Its contribution is described in the research at the level of the whole compound rather than separately.
Because one peptide carries all three activities, the receptors are engaged simultaneously rather than through separate compounds — the design premise the large-scale Phase 3 program was built to test.
What it's used to support.
Retatrutide is most relevant to women 35 and older already working with a practitioner on the wider metabolic picture — insulin resistance, changing body composition, a plateau that consistent habits have not moved. It suits those who want a multi-pathway option evaluated properly, within a supervised plan, rather than pursued on its own.
The figures above are the amount of lyophilized peptide in the vial — they are not a dose, and which presentation is appropriate is part of the conversation. Your protocol, timing, and duration are set one-to-one with a licensed practitioner based on your history and goals.
The specifics, if you want them.
Technical specifications
Where the research stands
Retatrutide has been studied in a large-scale Phase 3 clinical program, which places its evidence base well ahead of most peptides discussed here. It is not, however, a settled compound: the trials are recent, long-term data are still accumulating, and questions of durability and long-term safety remain open. We describe it as under active clinical study, not as established.
Storage & handling
Before you start.
That is decided in consultation, not on this page. Route, dose, and schedule depend on your metabolic history, what you are already taking, and what your practitioner is working to move. Vial presentations of 10 mg, 20 mg, and 30 mg describe vial content only — they are not doses, and should never be read as one.
We do not attach a timeline to it. Metabolic response varies with baseline, with what else is in the plan, and with how the protocol is built around you. What is worth tracking, and over what stretch, is a question for the practitioner who knows your baseline.
Yes. Retatrutide acts on three metabolic receptors at once, and that breadth is why oversight here is continuous rather than initial. A licensed practitioner needs to review your history, your current medications, and your metabolic markers before anything begins — and to stay with it while the protocol runs.
Because appetite, glucose handling, and energy expenditure are not separate problems. Single-receptor and dual-receptor peptides address part of that system; Retatrutide was designed to engage GLP-1, GIP, and glucagon together, rather than one or two of them. Whether that translates into a meaningful difference for any given person is a question for your practitioner.
It means human trials, not animal work. Retatrutide has moved through a large-scale Phase 3 clinical program, which is a higher tier of evidence than most compounds in this catalog carry. It does not mean the questions are closed — it means the research is human, ongoing, and read carefully rather than quoted selectively.
Every Inner Peptides formula is independently tested before it ships, with a Certificate of Analysis available on request. Learn more about our testing standard.
